ImmunoGen, Inc. (IMGN) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
830 WINTER ST WALTHAM, MA 02451 |
| State of Incorp. | MA |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in millions)Annual | Quarterly
| 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 310 | 374 | 438 | 479 | 246 | 240 | 283 | ||
| Cash and cash equivalents | 310 | 374 | 438 | 479 | 246 | 240 | 283 | ||
| Receivables | 1 | 3 | 5 | 7 | 5 | 4 | 5 | ||
| Other undisclosed current assets | 20 | 17 | 14 | 14 | 20 | 31 | 31 | ||
| Total current assets: | 330 | 394 | 457 | 500 | 271 | 274 | 320 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 11 | 11 | 12 | 12 | 13 | 13 | 14 | ||
| Property, plant and equipment | 4 | 4 | 4 | 5 | 5 | 5 | 5 | ||
| Other noncurrent assets | 13 | 13 | 9 | 9 | 9 | 9 | 7 | ||
| Total noncurrent assets: | 28 | 28 | 25 | 26 | 26 | 27 | 26 | ||
| TOTAL ASSETS: | 359 | 422 | 482 | 526 | 297 | 301 | 346 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 85 | 59 | 48 | 47 | 50 | 44 | 49 | ||
| Accounts payable | 20 | 17 | 16 | 18 | 11 | 12 | 13 | ||
| Accrued liabilities | 56 | 37 | 29 | 23 | 35 | 29 | 33 | ||
| Employee-related liabilities | 9 | 5 | 3 | 5 | 5 | 4 | 3 | ||
| Deferred revenue | 15 | 16 | 23 | 44 | 54 | 54 | 52 | ||
| Debt | 1 | 2 | |||||||
| Other undisclosed current liabilities | 4 | 13 | 13 | 10 | 8 | 21 | 32 | ||
| Total current liabilities: | 104 | 87 | 84 | 101 | 112 | 120 | 134 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 12 | 13 | 14 | 15 | 16 | 17 | 18 | ||
| Operating lease, liability | 12 | 13 | 14 | 15 | 16 | 17 | 18 | ||
| Liabilities, other than long-term debt | 39 | 44 | 47 | 49 | 55 | 58 | 61 | ||
| Deferred revenue | 39 | 44 | 47 | 48 | 52 | 55 | 59 | ||
| Other liabilities | 0 | 0 | 1 | 1 | 2 | 2 | 2 | ||
| Other undisclosed noncurrent liabilities | 26 | 28 | 29 | 35 | 37 | 38 | 39 | ||
| Total noncurrent liabilities: | 77 | 85 | 91 | 99 | 108 | 113 | 117 | ||
| Total liabilities: | 181 | 172 | 175 | 200 | 220 | 233 | 252 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 178 | 250 | 306 | 326 | 77 | 68 | 94 | ||
| Common stock | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||
| Additional paid in capital | 1,811 | 1,805 | 1,800 | 1,795 | 1,509 | 1,463 | 1,458 | ||
| Accumulated deficit | (1,635) | (1,557) | (1,495) | (1,471) | (1,434) | (1,397) | (1,366) | ||
| Total stockholders' equity: | 178 | 250 | 306 | 326 | 77 | 68 | 94 | ||
| TOTAL LIABILITIES AND EQUITY: | 359 | 422 | 482 | 526 | 297 | 301 | 346 | ||
Income Statement (P&L) ($ in millions) Annual | Quarterly
| 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 15 | 14 | 38 | 28 | 9 | 17 | 16 | |
| Gross profit: | 15 | 14 | 38 | 28 | 9 | 17 | 16 | |
| Operating expenses | (93) | (75) | (61) | (63) | (43) | (44) | (45) | |
| Operating loss: | (77) | (61) | (23) | (35) | (34) | (27) | (29) | |
| Nonoperating income (expense) | 1 | 0 | (0) | (0) | (0) | 0 | (0) | |
| Investment income, nonoperating | 2 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Other nonoperating income (expense) | (1) | (0) | (0) | (0) | (0) | 0 | (0) | |
| Interest and debt expense | (0) | (0) | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (77) | (61) | (23) | (35) | (35) | (27) | (29) | |
| Other undisclosed loss from continuing operations before income taxes | (13) | |||||||
| Loss before gain (loss) on sale of properties: | (77) | (61) | (23) | (48) | (35) | (27) | (29) | |
| Other undisclosed net income (loss) | (1) | 11 | (5) | |||||
| Net loss: | (77) | (61) | (24) | (37) | (35) | (27) | (34) | |
| Other undisclosed net loss attributable to parent | (1) | (1) | (3) | (4) | ||||
| Net loss available to common stockholders, diluted: | (78) | (62) | (24) | (37) | (37) | (31) | (34) | |
Comprehensive Income ($ in millions)Annual | Quarterly
| 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (77) | (61) | (24) | (37) | (35) | (27) | (34) | |
| Comprehensive loss: | (77) | (61) | (24) | (37) | (35) | (27) | (34) | |
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (1) | (1) | (3) | (4) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (78) | (62) | (24) | (37) | (37) | (31) | (34) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.